ライフサイエンスコーパス: median survival

1 vity, and antigen-site density most impacted median survival.

2 oss all age and EF groups had markedly lower median survival.

3 care; prognosis is poor, with 4- to 6-month median survival.

4 hibition of tumor growth and prolonged mouse median survival.

5 accelerates tumour development and shortens median survival.

6 was associated with worsening FEV1 and lower median survival.

7 between injections led to a 10% reduction in median survival.

8 SOD1(A4V) survival probability (median survival 1.2 years) was significantly decreased c

9 ed OS in patients with untreated metastases (median survival 10 vs 38 months, P < 0.001).

10 s (median survival=40days), cisplatin alone (median survival=12days) or saline-treated controls (medi

11 ypermetabolism was associated with a reduced median survival [14.6 compared with 21.4 mo, respectivel

12 70%, P<0.01), and a trend for longer overall median survival (15.4 versus 9.3 months, P=0.72) yet not

13 MM patients without prior knowledge of MGUS (median survival, 2.1 years), although MM patients with (

14 0.77-0.96; P < .01) better overall survival (median survival, 2.8 years) than MM patients without pri

15 tages (28.5% vs 10.1%; P = 0.002), and lower median survival (20.9 vs 41.0 mos; P = 0.001).

16 n in tumor size (P < 0.001) and an increased median survival (207 d; interquartile range [IQR], 132-2

17 HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-nega

18 urvival was recorded between the two groups (median survival 23.4 months [95% CI 20.9-24.8] with doce

19 vided the most significant survival benefit (median survivals: 24.8 vs 21.0 mo for adjuvant chemother

20 ted with improved survival compared with UR (median survival, 26 months v 21 months, respectively; st

21 survival=12days) or saline-treated controls (median survival=28days).

22 patients with EGFR mutations had the longest median survival (3.51 years; 95% CI, 2.89 to 5.5 years),

23 port cells succumbed to bone marrow failure (median survival, 328 days) characteristic of myelodyspla

24 st one MRLN by EUS was associated with lower median survival (353 vs 1050 days, p<0.001) and increase

25 st one MRLN by EUS was associated with lower median survival (353 vs. 1,050 days; P < 0.001) and incr

26 atin in conventional un-PEGylated particles (median survival=40days), cisplatin alone (median surviva

27 those with no high-risk pathologic features (median survivals: 54.6 vs 42.7 mo for adjuvant chemother

28 antly decreased compared with SOD1(non-A4V) (median survival 6.8 years; p<0.0001, log-rank).

29 ith triple-negative subtype had the shortest median survival (6.0 months).

30 ached </= 0.2 ng/mL compared with > 4 ng/mL (median survival, 60.4 v 22.2 months, respectively; P < .

31 roduced acute leukemia with a short latency (median survival, 67 days).

32 cant for patients with pleural mesothelioma (median survival 7.9 y versus 2.4 y, P = 0.0012), but not

33 ival compared with vehicle-treated controls (median survival, 7.8 vs. 4.5 mo; P = 0.001).

34 io was 0.98 (95% CI, 0.80 to 1.20; P = .847; median survival, 70 months) for SOC + Cel and 0.86 (95%

35 Cel and 0.86 (95% CI, 0.70 to 1.05; P =.130; median survival, 76 months) for SOC + ZA + Cel.

36 t for patients with peritoneal mesothelioma (median survival 8.2 y versus 5.4 y, P = 0.47).

37 Median survival according to cause of dropout (LAD, EHD,

38 he remaining 56 patients was 32 months, with median survival after discontinuation of 14 months.

39 Median survival after first infection-related hospitaliz

40 Median survival after MHS onset was 28 months (range, 3

41 The median survival after surgery for LAPC was 20.1 months a

42 Median survival among all patients was 21.1 months [95%

43 Median survival among the entire cohort with brain metas

44 as been demonstrated to significantly extend median survival and achieve a high rate of complete tumo

45 Kaplan-Meier estimates of median survival and descriptive statistics were used to

46 the five BMI categories was graded based on median survival and prognostic significance.

47 Inevitable tumor recurrence and a poor median survival are frustrating reminders of the ineffic

48 homa in mice at seemingly similar paces with median survival around 10 and 11 weeks, respectively, co

49 ne of the most lethal cancers, with a dismal median survival around 8 months.

50 CLL, where have more aggressive disease with median survivals around eight years.

51 The CCR2 antagonist CCX872 increased median survival as a monotherapy in KR158 glioma-bearing

52 nt to normal level, and significantly longer median survival as compared to free drugs or untargeted

53 cted with 3 x 10(5) GL261-Luc2 cells reached median survival at 23 days.

54 Red-FLuc implanted mice cells did not reach median survival at any tumor dose.

55 g patients with decompensated cirrhosis, the median survival benefit was 31 days, and it was not cost

56 This therapy extended median survival by 50% and delayed hindlimb paralysis, w

57 nosis with amyloidosis was 45 months (2-89); median survival by amyloidosis type was localized AL: 64

58 re typically have more indolent disease with median survivals close to 25 years, and Ig-mutated CLL,

59 of pancreatic cancer and nearly triples the median survival compared to controls.

60 , hospital stay, perioperative mortality, or median survival compared to the younger group.

61 ion and resulted in twice the improvement in median survival compared with T-DM1 alone.

62 phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing primary surgery followed by sy

63 Above 1 MBq, the median survival decreased linearly with injected activit

64 fidence interval [CI], 1.21-3.56; p = 0.008; median survival difference = 4.7 years).

65 -) and Cd74(-/-) mice demonstrated decreased median survival following hyperoxia compared to WT mice.

66 Median survival for glioblastoma (GBM) remains <15 month

67 The median survival for glioblastoma patients is 15 months d

68 The median survival for glioblastoma patients is ~15 months

69 The median survival for HIV patients who underwent biopsy in

70 Median survival for mice implanted with 5 x 10(4) GL261

71 Median survival for older adults was 175 days (95% CI, 1

72 The estimated median survival for patients randomized to ALPPS was 46

73 th blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 1

74 Median survival for recipients of older donors was reduc

75 The median survival for SCLC remained 7 months, and the 12-m

76 The overall median survival for the cohort in the present study was

77 Median survival for the groups treated with phosphate-bu

78 the age- and sex-matched control population; median survivals for patients younger than 60 years are

79 ficantly impaired tumor growth and prolonged median survival from 13 d (phosphate-buffered saline) to

80 phaPD-1, inhibited tumor growth and extended median survival from 28 days (non-treatment control) to

81 these mice was associated with an increased median survival from approximately 5.5 to 7.5 mo and inc

82 However, median survival from cure is excellent at about 40 years

83 Median survival from diagnosis in patients with pulmonar

84 graft survival was 185 months (96-269), and median survival from diagnosis with amyloidosis was 45 m

85 om onset was 9.8 years (95% CI 8.8-10.7) and median survival from enrolment was 1.8 years (0.9-2.7).

86 None developed KSHV-MCD; 6 died with median survival from KICS diagnosis 13.6 months.

87 Median survival from study entry was similar for women (

88 Median survival from symptom onset was 9.8 years (95% CI

89 There was a significant increase in overall median survival from the 1970s to 2000s (2 vs. 8 months;

90 rutinib for up to 3 months, with 19.8 months median survival from the time of progression.

91 Median survival from time of recurrence to death was 21

92 Median survival gains of 1.5 months were observed.

93 % of patients with metastatic melanoma, with median survival > 3 years.

94 Median survival improved with dietary pancreatic enzyme

95 Median survival in arm A was 34.6 months, versus 54.8 mo

96 ge cross-sectional muscle area, and extended median survival in DM1 flies.

97 Median survival in patients staged as T3, N0 by the 7th

98 Median survival in patients with hepatocellular carcinom

99 Median survival in the metformin group was 5 months, com

100 a small-molecule antagonist of CCR4 improved median survival in the model.

101 Observed and predicted median survival in the training and internal validation

102 Observed median survival in the training and internal validation

103 method, which shows significant extension of median survival in two patient-derived BTIC xenograft mo

104 h inhibitors of JAK/STAT signaling, doubling median survival in vivo.

105 Among the 21372 patients, the median survival increased from 20 months (1988-1991) to

106 The median survival is <6 months when AL patients are untrea

107 ression and hinders effective treatment; the median survival is 16 mo despite standard-of-care therap

108 GB patients' median survival is 16 months even with treatment.

109 otherapy and, if age permits, radiotherapy), median survival is 17 months(1,2).

110 RCCs (sRCCs) have shown little efficacy, and median survival is commonly 6-13 months.

111 fluoropyrimidine doublet in the first line; median survival is less than 1 year.

112 Median survival is less than 6 months.

113 The median survival is only 5 mo, and the 1-y survival is le

114 multimodal standard treatments for GBM, the median survival is still about one year.

115 omatic, and this, in combination with a long median survival, led to the initial studies of observing

116 is highly invasive and uniformly fatal, with median survival<20months after diagnosis even with the m

117 The median survival, measured from biopsy diagnosis, was 46.

118 Because of their relatively long overall median survival, more aggressive treatments are typicall

119 e III, and 16% had stage IIIb disease with a median survival not reached in stage I, 9.4 years in sta

120 elivered in brain penetrating nanoparticles (median survival not reached; 80% long-term survivors) co

121 yndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years.

122 advanced cancer diagnosis for patients with median survival of 1 year or less, and progressive disea

123 s reported for patients with ovarian cancer (median survival of 11-14 months), 50-91% for gastric can

124 ients was 4.9 years (range 0.3-39.6), with a median survival of 11.4 years.

125 Responders had a median survival of 113 days (95% CI 41-186) compared to

126 rtality of 44.4/100 person-years (PYs) and a median survival of 13.5 months after the diagnosis of CM

127 adiation and chemotherapy, only results in a median survival of 14 months, underscoring the importanc

128 oup that received the BCNU alone wafer had a median survival of 15 days, the group that received the

129 8-15 months), 71-86% for colorectal cancer (median survival of 16 months), and 67-75% (median surviv

130 roup that received the TMZ wafer alone had a median survival of 19 days, and the group treated with t

131 nary fibrosis is a fatal lung disease with a median survival of 2 to 5 years.

132 degenerative disease of motor neurons with a median survival of 2 years.

133 duced survival compared with the SAVR group (median survival of 2.8 vs. 4.4 years; P = 0.047).

134 ith high risk of metastasis and an estimated median survival of 2.9 y.

135 lastic leukemia at 100% incidence and with a median survival of 21 wk.

136 (median survival of 16 months), and 67-75% (median survival of 27 months) for peritoneal mesotheliom

137 of 2.7/100 PYs (P < 0.001) and an estimated median survival of 27.0 years after the diagnosis of CMV

138 ts receiving surgical therapy (n = 25) had a median survival of 27.8 months, significantly superior t

139 group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals livin

140 (firefighters/police) was associated with a median survival of 28.6% (range, 9.0-76.0).

141 ts experience frequent relapses resulting in median survival of 3 to 5 years, requiring more efficien

142 progressive interstitial lung disease with a median survival of 3 years after diagnosis.

143 erative disorder with a poor prognosis and a median survival of 3 years.

144 scharge after OHCA treated with PAD showed a median survival of 40.0% (range, 9.1-83.3).

145 associated with the highest survival with a median survival of 53.0% (range, 26.0-72.0), whereas def

146 compared with controls was observed, with a median survival of 55 d for 277.5 kBq of (212)Pb-daratum

147 on compared to controls was observed, with a median survival of 55 days for 277.5 kBq of (212)Pb-Dara

148 has resulted in marrow CR rates of 55% and a median survival of 6 to 7 months when given to patients

149 n overall response rates of 40% to 50% and a median survival of 6.5 months in a similar refractory-re

150 studied for the creation of the DS-GPA had a median survival of 7 months from the time of initial tre

151 nsplantation at the time of the study with a median survival of 7.0 (4.4-14.5) years.

152 atients (<10 points) demonstrating excellent median survival of 70.6 months, significantly superior t

153 arise rapidly in this model that displays a median survival of 76 days.

154 of 11-14 months), 50-91% for gastric cancer (median survival of 8-15 months), 71-86% for colorectal c

155 those who preferred inotropes over LVAD had median survival of 9.0 months (interquartile range, 3.1-

156 and increased risk of death due to lymphoma (median survival of 9.5 years with BCL2 mutations vs 20.4

157 Median survival of 937 patients was 22.1 months.

158 Ctbp2 heterozygosity increased the median survival of Apc(min/+) mice from 21 to 48 weeks,

159 rity of SMZLs show an indolent course with a median survival of approximately 10 years, nearly 30% of

160 noma, which has a very poor prognosis with a median survival of less than 1 y.

161 mas (GBMs) are malignant brain tumors with a median survival of less than 18 months.

162 s the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical re

163 s a mortality rate of approximately 100% and median survival of less than 5 months.

164 cancer, which is associated with an overall median survival of less than 5 years from diagnosis.

165 carcinomas have a very poor prognosis with a median survival of less than a year.

166 Median survival of metformin users versus nonusers was 9

167 loss of just one allele of Moz increased the median survival of mice by 3.9-fold.

168 with BA and ibrutinib markedly improved the median survival of mice engrafted with the MCL cells.

169 211At-CD38 at 15 to 45 uCi at least doubled median survival of mice relative to untreated controls (

170 esveratrol treatment significantly increased median survival of mice with HF, lessened cardiac fibros

171 ression in the prostate tumors (n=8); with a median survival of more than 60 days compared to 12 days

172 a and Lung-molGPA scores of 3.5 to 4.0 had a median survival of nearly 4 years.

173 a onset was rapid in triple-CKO mice, with a median survival of only 12 weeks, and malignant mesothel

174 owed significant weight loss, resulting in a median survival of only 24 d.

175 The median survival of patients achieving a pathologic compl

176 Incidence proportion and median survival of patients with brain metastases and ne

177 The median survival of patients with LEE was lower than that

178 Median survival of relapsing patients was 59 months.

179 The median survival of single-organ metastasis was better th

180 potent therapeutic effect and prolonged the median survival of TET1-high AML mice over three fold.

181 The median survival of the different categories was signific

182 Median survival of the group was 37 months (6-40).

183 cleaved caspase-3, and leads to a prolonged median survival of the mice (36.5 vs. 22.5 d, respective

184 The median survival of the sorafenib-treated patients was 15

185 e 5-year outcomes and to compare survival to median survival of the U.S.

186 r patients develop brain metastasis, and the median survival of these patients remains less than 6 mo

187 The median survival of TKO pig kidneys (4 days) in baboons w

188 s and results in a profound extension of the median survival of treated animals.

189 ies also defines better outcome groups, with median survivals of 15.9 versus 9.2 months (P = 0.029) a

190 o characterize the incidence proportions and median survivals of patients with breast cancer and brai

191 ays, resulted in a simulated 31% increase in median survival over a single 400 nCi administration.

192 MD treatment was further shown to extend the median survival period from less than 20days in the cont

193 y, culminating in haemorrhagic ascites and a median survival period of 7.5 weeks.

194 brain cancer patients remains dismal and the median survival rarely exceeds 16 months.

195 In comparison with a median survival rate of 12.9% (interquartile range, 11.1

196 Median survival rates were 43.5, 61, and 71 d for the co

197 With increasing numbers of PLN median survival significantly decreased (2-3 PLN: 26.1 m

198 t patients with dysphagia at diagnosis had a median survival similar to bulbar onset patients.

199 onths (95% CI, 24.8 to 41.3 months), whereas median survival since the time of SCLC transformation wa

200 ts receiving PRRT had a significantly longer median survival than patients not receiving PRRT (4.4 vs

201 resulted in a significant improvement in the median survival time (24.5 days for saline, 26 days for

202 iously reported IDEC-131-treated allografts, median survival time (35 +/- 31 days) was significantly

203 mice brain with significant increase in the median survival time (36 days) along with no toxicity.

204 , fibrosis, and apoptosis; and prolonged the median survival time 2-fold in the myocyte-specific Lmna

205 76% in patients who received other regimens (median survival time 223 days).

206 was 65% overall, 48% in the BDex+AA cohort (median survival time 821 days), and 76% in patients who

207 The median survival time after HCC diagnosis for persons wit

208 ediction was assessed by using difference in median survival time and area under the curve with time-

209 r differentiation according to difference in median survival time between high- and low-risk groups (

210 Predicted median survival time calculated according to the Helsink

211 ference, the number needed to treat, and the median survival time difference.

212 ombination of CCX872 and anti-PD-1 prolonged median survival time in 005 GSC GBM-bearing mice.

213 es, resulting in significant improvements in median survival time in a B16-F10 melanoma model.

214 levant tissues and a significant increase in median survival time in a dose-dependent manner.

215 The median survival time in the FOLFOX plus SIRT group was 2

216 ose-dependent therapeutic response, with the median survival time increasing from 68 d for the lowest

217 PG) is a lethal pediatric brain cancer whose median survival time is under one year.

218 hose with an SUVr of at least 2.5, who had a median survival time of 10.1 (95% CI: 2.4, 15.9; P = .00

219 deaths from lung cancer were documented with median survival time of 10.3 months (interquartile range

220 glioblastoma with a penetrance of 92% and a median survival time of 105 d.

221 nths), 71.6% of patients were deceased, with median survival time of 11 months for those who died.

222 tients with SUVr of less than 1.7, who had a median survival time of 23.1 months (95% confidence inte

223 Survival analysis demonstrated a median survival time of 24 months (95% confidence interv

224 (+) T cells and rejected their grafts with a median survival time of 27 days.

225 al pneumonia, is a fatal lung disease with a median survival time of 3-5 years.

226 leading cause of cancer-related death with a median survival time of 6-12 months.

227 astoma is a universally lethal cancer with a median survival time of approximately 15 months.

228 available for patients with DIPG, who have a median survival time of less than one year.

229 e growth of T24 xenografts and increases the median survival time of nude mice.

230 Median survival time of rats bearing orthotopic glioma w

231 and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53(-/-) mice, which dev

232 The median survival time of the entire cohort was 9.2 months

233 nd initial respiratory impairment, and had a median survival time similar to bulbar onset patients.

234 The median survival time was 14 months.

235 after a diagnosis of esophageal cancer, the median survival time was 14.9 months (IQR, 7.1-52.3 mo)

236 The median survival time was 16.3 (11.47-22.57) months, and

237 The median survival time was 26 years from disease onset.

238 The median survival time was 82 days (interquartile range [I

239 Median survival time without IRA failure was estimated a

240 estimated the time ratio (relative change in median survival time) per 100 working level months (rado

241 on in tumor progression, a 50.0% increase in median survival time, and a 26.6% increase in necrotic p

242 The median survival time, censored to liver transplantation,

243 M/DOX liposome-treated group had the longest median survival time, double that of the DOX liposome-tr

244 he Kaplan-Meier method to estimate patients' median survival time.

245 hallenge, ZWC more than doubles the animals' median survival time.

246 , as measured by bioluminescent imaging, and median survival time.

247 , respectively, and significant increases in median survival time.

248 days), limited weight loss (<5%), and longer median survival times (~18 days) that were significantly

249 h R0, R1 (<1 mm), and R1 (direct) status the median survival times and 5-year survival rates were 41.

250 The differences in median survival times between persons in the lower and u

251 The differences in median survival times between persons in the lower and u

252 Single organ lung metastasis had longer median survival times compared to the other sites (lung

253 toma (GBM) is an astrocytic brain tumor with median survival times of <15 months, primarily as a resu

254 ontrol antibody, anti-PD-1, or anti-OX40 had median survival times of 50 days or less, whereas mice g

255 ss (>10%) than the unvaccinated controls and median survival times that were not significantly differ

256 wth inhibition (p=0.001, ANOVA) and enhanced median survival to 27 days over controls.

257 Gene therapy results in an improvement in median survival to greater than 200 days.

258 iffuse large B-cell lymphoma (DLBCL) reduces median survival to only 1.2 years.

259 Although current standard therapy extends median survival to ~15 months, most patients do not have

260 static disease during neoadjuvant treatment, median survival was 10.5 months compared with 53 months

261 0.63 (95% CI 0.50-0.79; one-sided p<0.0001); median survival was 10.6 months (95% CI 9.1-12.1) for re

262 Median survival was 10.9 months (95% CI 6.2-14.7).

263 1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months.

264 Subgroup median survival was 16.0 months (Folfirinox) vs 16.5 mon

265 me was 28.2 months (range, 4-38 months), and median survival was 16.1 months (range, 0.1-60.3 months)

266 Overall, median survival was 2.1 years.

267 Median survival was 2.6 years from diagnosis.

268 Total SOD1 patient median survival was 2.7 years.

269 The median survival was 28.6 months.

270 Overall median survival was 35 mo, with a 1-, 2-, 5-, and 10-y s

271 y rate was 5.2%; median LOS was 15 days, and median survival was 38 months.

272 Modeled median survival was 39.4 months for TH and 56.9 months f

273 The median survival was 4.25 months (interquartile range, 1.

274 Median survival was 43, 46 and 84 days, for control, IRE

275 was 20 months (95% CI, 16 to 26 months), and median survival was 49 months (95% CI, 40 months to not

276 Overall median survival was 53 months and 1-, 3-, and 5-year sur

277 ontrol arm deaths (83% prostate cancer), and median survival was 66 months.

278 Median survival was 67.4 months.

279 Median survival was 82 days among the HIV-infected HCC p

280 Median survival was assessed by using Kaplan-Meier and l

281 Median survival was calculated by using the Kaplan-Meier

282 l subtype who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 mo

283 Median survival was improved in HSAs with higher resecti

284 vs. 0% for the paclitaxel only group and the median survival was increased by 86%.

285 Unadjusted median survival was longer for patients undergoing resec

286 Median survival was much shorter in Ile107Val and in Val

287 Median survival was not reached, 49 and 17 months for 0,

288 3 [44%] of 1315 in other African countries), median survival was shorter in the other African countri

289 After matching, median survival was significantly longer for extended ch

290 Median survival was significantly longer for vaccinated

291 However, median survival was significantly prolonged to 37 days i

292 Median survival was significantly shortened in overt PMF

293 Median survival was worse in the cTACE-B group than in t

294 After PSM, the 3-year survival rates and median survival were 44.9% and 27.2 (95% confidence inte

295 Although the time to recurrence and median survival were significantly longer for pN0 as com

296 Median survival with IP therapy was 61.8 months (95% CI,

297 acizumab (hazard ratio [HR], 0.86; P = .12); median survival with pemetrexed and bevacizumab was 16.4

298 With a median follow-up of 50.6 months, median survival with pemetrexed was 15.9 months, compare

299 prostate DKO) exhibited a markedly increased median survival with reduced tumor size and proliferatio

300 ificant tumor regression and prolonged mouse median survival without significant change in mouse body